The Centers for Medicare & Medicaid Services Friday released guidance clarifying federal requirements for health plans to cover certain items and services related to diagnostic testing for COVID-19 without cost-sharing, prior authorization or other medical management requirements.

The guidance also includes information on federal reimbursement for COVID-19-related services provided to the uninsured.

In other news, the Food and Drug Administration today issued an emergency use authorization for the Quidel QuickVue At-Home COVID-19 Test, a prescription antigen test that allows individuals to collect and test a sample at home when their health care provider suspects they have COVID-19 within six days of symptom onset.

The EUA requires Quidel to develop a mobile phone application or website to facilitate results reporting by the user and health care provider. A research team funded by the National Institutes of Health has launched a study to assess the app’s performance and usability.

Related News Articles

Headline
The monoclonal antibody therapy REGEN-COV (casirivimab with imdevimab) reduced the risk of symptomatic COVID-19 in household contacts of people with SARS-CoV-2…
Headline
The Food and Drug Administration and Centers for Disease Control and Prevention today jointly recommended a pause in the use of Johnson & Johnson’s…
Blog
Our doctors, nurses and clinical staff have responded to the COVID-19 pandemic with dedication and bravery. Yet, the pandemic’s longevity, as well as COVID-19’…
Headline
The Centers for Medicare & Medicaid Services will no longer waive certain requirements for long-term care and skilled nursing facilities beginning May 9 or…
Chairperson's File
One legacy of our response to COVID-19 surely will be how it has accelerated the adoption of virtual care. It is one of the more encouraging developments…
Headline
Pfizer today said it is seeking an amended emergency use authorization for its COVID-19 vaccine, requesting that the Food and Drug Administration allow…